MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
07 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Minimal Residual Disease Testing Market Growth Trends 2025-2031: Growing Use of MRD Testing In Cases of Solid Tumors
27 déc. 2024 05h00 HE
|
Research and Markets
Dublin, Dec. 27, 2024 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to...
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
08 oct. 2024 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research...
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
11 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL)...
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
09 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
Global Minimal Residual Disease Testing Market Projected to Surpass US$ 5.1 Billion by 2032, Driven by Technological Advancements, & Clinical Applications and End-User Engagement
03 mai 2024 05h29 HE
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing Market by Technology, Application, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's...
Global MRD Testing Market Projected to Reach $6.67 Billion by 2033, Driven by Advances in Cancer Detection Technology
19 mars 2024 12h23 HE
|
Research and Markets
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast,...
Asia-Pacific Measurable/Minimal Residual Disease (MRD) Testing Market Analysis 2023-2033 - Medicare Expansion and Rising Consumer Awareness Driving Growth
08 mars 2024 09h33 HE
|
Research and Markets
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific MRD Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The Asia-Pacific MRD...
Europe MRD Testing Market Report 2024: Analysis and Forecasts 2023-2033 Featuring Cergentis , F. Hoffmann-La Roche, and ICON
06 févr. 2024 09h12 HE
|
Research and Markets
Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Europe MRD Testing Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The Europe MRD testing market...
Global Minimal Residual Disease Testing Market Report 2023-2028 Featuring Key Players - Adaptive Biotechnologies, Invitae, Guardant Health, Natera, NeoGenomics, Exact Sciences, and Quest Diagnostics
30 août 2023 04h43 HE
|
Research and Markets
Dublin, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering. The global market for...